TransMedics Group (NASDAQ:TMDX) Upgraded to Strong-Buy at Zacks Research

Zacks Research upgraded shares of TransMedics Group (NASDAQ:TMDX) from a hold rating to a strong-buy rating in a research report released on Monday,Zacks.com reports.

Several other equities analysts have also commented on TMDX. Evercore ISI started coverage on shares of TransMedics Group in a research report on Tuesday, September 16th. They set an “outperform” rating and a $155.00 price objective for the company. Morgan Stanley increased their price objective on shares of TransMedics Group from $115.00 to $123.00 and gave the company an “equal weight” rating in a research report on Friday, August 1st. Stifel Nicolaus began coverage on shares of TransMedics Group in a research note on Thursday, September 4th. They issued a “hold” rating and a $115.00 target price on the stock. Canaccord Genuity Group increased their target price on shares of TransMedics Group from $129.00 to $142.00 and gave the company a “buy” rating in a research note on Tuesday, July 15th. Finally, Wall Street Zen downgraded shares of TransMedics Group from a “buy” rating to a “hold” rating in a research note on Saturday, August 30th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, TransMedics Group currently has a consensus rating of “Moderate Buy” and a consensus target price of $125.40.

TransMedics Group Price Performance

TMDX stock opened at $112.20 on Monday. TransMedics Group has a 52 week low of $55.00 and a 52 week high of $155.99. The company has a quick ratio of 9.17, a current ratio of 9.86 and a debt-to-equity ratio of 1.61. The company has a fifty day simple moving average of $116.57 and a two-hundred day simple moving average of $109.63. The firm has a market capitalization of $3.82 billion, a P/E ratio of 58.14 and a beta of 2.18.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings data on Wednesday, July 30th. The company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.48 by $0.44. TransMedics Group had a net margin of 13.49% and a return on equity of 28.02%. The business had revenue of $157.37 million during the quarter, compared to analyst estimates of $146.64 million. During the same quarter last year, the business earned $0.35 earnings per share. TransMedics Group’s quarterly revenue was up 37.7% compared to the same quarter last year. TransMedics Group has set its FY 2025 guidance at EPS. Analysts anticipate that TransMedics Group will post 1 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in TransMedics Group by 244.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,113,082 shares of the company’s stock worth $209,448,000 after buying an additional 2,209,996 shares during the period. Geode Capital Management LLC increased its stake in TransMedics Group by 1.4% in the 2nd quarter. Geode Capital Management LLC now owns 804,650 shares of the company’s stock worth $107,845,000 after buying an additional 11,241 shares during the period. Driehaus Capital Management LLC increased its stake in TransMedics Group by 2.4% in the 1st quarter. Driehaus Capital Management LLC now owns 778,754 shares of the company’s stock worth $52,395,000 after buying an additional 17,913 shares during the period. Marshall Wace LLP increased its stake in TransMedics Group by 258.7% in the 2nd quarter. Marshall Wace LLP now owns 546,787 shares of the company’s stock worth $73,275,000 after buying an additional 394,340 shares during the period. Finally, Goldman Sachs Group Inc. increased its stake in TransMedics Group by 20.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 507,510 shares of the company’s stock worth $34,145,000 after buying an additional 86,721 shares during the period. Hedge funds and other institutional investors own 99.67% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.